Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Heart Test Laboratories, Inc. - Warrant
(NQ:
HSCSW
)
0.0374
UNCHANGED
Streaming Delayed Price
Updated: 12:16 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Heart Test Laboratories, Inc. - Warrant
< Previous
1
2
Next >
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
July 29, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
July 26, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
July 25, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
July 11, 2024
Further expands HeartSciences extensive patent portfolio
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Regains Compliance with Nasdaq Listing Requirements
June 04, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
May 20, 2024
Granted Indian Patent for its MyoVista® Wavelet Technology
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
April 24, 2024
Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences to Present at the LD Micro Invitational XIV Conference
April 02, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
March 26, 2024
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
March 14, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
March 12, 2024
Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screening
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
March 06, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Adds Key Advisor to its Scientific Advisory Board
February 26, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Expands its Scientific Advisory Board
February 12, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Appoints New Scientific Advisory Board Member
February 01, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
January 18, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
January 03, 2024
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
December 14, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
December 05, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
November 20, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
November 13, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
September 26, 2023
Patents Cover MyoVista® Wavelet Technology Utilizing AI for Early Detection of Heart Disease
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.
September 25, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms
September 21, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
September 14, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
September 12, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards
September 11, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India
September 07, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences Signs Distribution Agreement with FJ Medical, Denmark
August 31, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
HeartSciences’ MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation
August 24, 2023
From
Heart Test Laboratories, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.